Bellus Health Announces Positive End-of-Phase 2 Meeting with the FDA and its CALM Phase 3 Program for BLU-5937 in Refractory Chronic Cough Pharmaceutical Investing
Lobe Sciences Ltd. Announces Regulatory and Clinical Development Plans For 2022 and Early 2023 Pharmaceutical Investing
BetterLife Secures Additional Mitacs Funding in Collaboration with Carleton University Research Team for BETR-001 Preclinical Depression Studies Pharmaceutical Investing
BriaCell Partners with Waisman Biomanufacturing to Manufacture and Supply Prostate Cancer Immunotherapy Pharmaceutical Investing
Pfizer Announces Submission of New Drug Application to the U.S. FDA for PAXLOVID Pharmaceutical Investing
Pfizer and BioNTech Announce New Agreement with U.S. Government to Provide Additional Doses of COVID-19 Vaccine Pharmaceutical Investing
